IHS and ACP Guidelines Differ on Migraine Treatment Approaches

Overview

The International Headache Society (IHS) and American College of Physicians (ACP) offer differing recommendations for acute and preventive migraine treatments. While IHS favors oral triptans as first-line acute therapy, ACP recommends combining triptans with NSAIDs or acetaminophen. Preventive treatment guidelines vary, especially regarding the use of costly CGRP-targeting therapies.

Background

Migraine management involves both acute and preventive strategies tailored to patient-specific factors such as headache frequency, comorbidities, and prior treatment response. Acute treatments include NSAIDs, triptans, and gepants, each with varying efficacy and safety profiles. Preventive therapies aim to reduce monthly migraine days, with newer CGRP-targeting agents offering faster onset but at higher costs. Guideline recommendations differ, reflecting limited comparative evidence and considerations of safety, efficacy, and cost.

Data Highlights

Key Findings

• IHS recommends oral triptans as first-line acute migraine therapy; ACP recommends triptans combined with NSAIDs or acetaminophen.
• Triptans generally show higher efficacy than NSAIDs and gepants for achieving pain freedom at 2 hours, with eletriptan being the most effective.
• Gepants have lower relative effectiveness but do not cause medication overuse headache and are suitable for patients with contraindications to triptans.
• Preventive therapy evidence is limited; most trials show no significant efficacy differences among treatments.
• CGRP-targeting therapies provide faster onset and better tolerability but are costly; ACP recommends reserving them for patients unresponsive to oral preventives, while IHS does not specify sequencing.
• Management should be individualized considering headache patterns, comorbidities, reproductive goals, and risk of medication overuse.

Clinical Implications

Clinicians should consider triptans as first-line acute treatment but may combine them with NSAIDs or acetaminophen for enhanced efficacy, per ACP guidance. Gepants offer a valuable alternative for patients with cardiovascular risks or medication overuse concerns. Preventive therapy choice should be personalized, weighing efficacy, side effects, and patient preferences. CGRP-targeting agents may be reserved for refractory cases due to cost and limited long-term safety data.

Conclusion

Migraine treatment guidelines from IHS and ACP differ in acute and preventive strategies, reflecting varying interpretations of efficacy, safety, and cost data. Patient-centered approaches remain essential to optimize outcomes.

References

1. Annals of Internal Medicine -- IHS, ACP Differ on Migraine Treatment